Skip to content

Remifentanil and Midazolam on Propofol for Loss of Consciousness

The Effect of Remifentanil and Midazolam on Propofol for Loss of Consciousness During Induction of Anesthesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02536690
Enrollment
120
Registered
2015-09-01
Start date
2015-08-31
Completion date
2016-05-31
Last updated
2016-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Keywords

propofol, midazolam, remifentanil, combination, synergic, pharmacodynamics, Loss of consciousness

Brief summary

Propofol in combination with remifentanil or midazolam can result in synergistic or additive effect. The patients who are scheduled to undergo general anesthesia are enrolled in this study. 120 patients will be randomly allocated to 3 groups(P, PR, PMR). The patients in group P will receive general anesthesia only with propofol and group PR and PMR will receive 0.25 mcg/kg/min remifentanil infusion prior to propofol. The patients in group PMR will receive 0.03 mg/kg bolus dose of midazolam 1 min after start of the remifentanil infusion. 'Success' is defined as loss of both verbal response and eyelash reflex in 2 min after propofol administration. When 'success', the next patient will receive the same dose(in 18/19 probability) or 0.25 mg/kg lower dose(in 1/19 probability) of propofol. When 'failure', the next patient will receive 0.25 mg/kg higher dose of propofol at induction period.

Detailed description

Propofol is a well-known induction agent which can provide sound and quick hypnosis with anti-emetic effects. However, dose dependent hypotension or bradycardia have reported while using this agent. Propofol in combination with remifentanil or midazolam can result in synergistic or additive effect. There are not many studies which provide minimum dose of propofol to induce hypnosis in combination with these agents and advantage of the combination. The patients who are scheduled to undergo general anesthesia are enrolled in this study. 120 patients will be randomly allocated to 3 groups(P, PR, PMR). Sample size have been decided due to the previous studies which have mentioned 40 participants as a adequate sample size for this biased coin design - up and down study. After receiving informed consent, patients will be participated in this study. No premedication will be given to the patients before induction. The patients in group P will receive general anesthesia only with propofol and group PR and PMR will receive 0.25 mcg/kg/min remifentanil infusion for 5 min prior to propofol administration. The patients in group PMR will receive 0.03 mg/kg bolus dose of midazolam 1 min after the start of the remifentanil infusion. Initial propofol dose will be 1 mg/kg in each group and the dose will be changed by the result of prior study participant. 'Success' of this study will be defined as loss of both verbal response and eyelash reflex in 2 min after propofol administration. When 'success', the next patient will receive the same dose(in 18/19 probability) or 0.25 mg/kg lower dose(in 1/19 probability) of propofol. When 'failure', the next patient will receive 0.25 mg/kg higher dose of propofol at induction period.

Interventions

DRUGPropofol

Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.

DRUGRemifentanil

Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.

DRUGMidazolam

Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.

Sponsors

Severance Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* The patients who are scheduled to undergo general anesthesia for a surgery.

Exclusion criteria

1. ASA class (American Society of Anesthesiologist physical status classification) II or higher 2. Patients with history of allergy or side effects on propofol, remifentanil, midazolam 3. BMI (body mass index) less than 20 or higher than 30 4. Pregnancy 5. Patients taking sedatives or hypnotic agents.

Design outcomes

Primary

MeasureTime frameDescription
Loss of verbal response and eyelash reflex2 minutes after propofol administrationChecking verbal response by verbal stimulation (yes or no) and reflex by palpation of the levator palpebrae (yes or no).

Secondary

MeasureTime frameDescription
Mean blood pressurebaseline, propofol administration time (Just after finishing monitoring on the patient in P group, 5 minutes after remifentanil infusion start in PR and PMR group), 1 minute and 2 minutes after propofol administrationTo compare differences among groups in mean blood pressure change (mmHg).
Heart ratebaseline, propofol administration time (Just after finishing monitoring on the patient in P group, 5 minutes after remifentanil infusion start in PR and PMR group), 1 minute and 2 minutes after propofol administrationTo compare differences among groups in heart rate change (mmHg).

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026